The 0.25x P/B is the lowest among the peer group (ACB at 0.71x, CRON at 1.09x), but this discount is mechanically driven by a combination of depressed market capitalization and a still-inflated book value that includes $752 million of goodwill — roughly 47% of current equity. Given that goodwill has already been written down by approximately $2 billion, investors should treat the P/B ratio as a lagging indicator that may not reflect the true replacement value of TLRY's operating assets. The forward EV/EBITDA of 25.6x, when readable, suggests the market is not pricing near-term earnings recovery, which is consistent with a company whose operating margin has been negative in eight of the last ten quarters.

Operating margin has been negative in eight of ten quarters, with the sole positive reading of +1.0% in 2026Q1 proving unsustainable as subsequent quarters returned to losses of -1.6% to -10.2%. Net margin tells an even darker story, with cumulative quarterly losses averaging roughly -15%, heavily distorted by non-cash impairment charges in 2025Q3-Q4 that make the underlying operating trajectory difficult to isolate. The persistent negative FCF margin — averaging approximately -9% across ten quarters — confirms that even adjusted for non-cash items, TLRY's earning power is structurally impaired relative to its cost base.

The pattern of ROIC improvement from -17.9% (2025Q3) to -0.7% (2027Q1) is almost entirely attributable to a 61% collapse in total assets — from $5.9 billion to $2.3 billion — which mathematically reduces the denominator without any corresponding improvement in returns. ROE tells the same story: the -58.7% reading in 2025Q4 followed by -2.5% in 2027Q1 reflects equity destruction from $4.7 billion to $1.6 billion, not a genuine turn in profitability. Investors should recognize that the apparent convergence toward breakeven ROIC is an accounting artifact of asset writedowns, not evidence of capital efficiency.

The low D/E ratio initially suggests a conservatively capitalized balance sheet, but this is misleading: with ROIC persistently negative, even minimal leverage becomes unserviceable from operations. The D/EBITDA reading of 115.99x in 2027Q1, while technically calculable, reflects an EBITDA figure so close to zero that the ratio is analytically meaningless — it signals that TLRY is operating at the boundary of cash-flow break-even rather than generating meaningful debt-service capacity. Given that the company still has debt on the balance sheet and negative operating cash flow in most quarters, refinancing risk appears manageable in the near term but warrants monitoring if burn accelerates.

The 101-day increase in DPO is a striking signal that TLRY has extended payment terms with suppliers by roughly 2.5x in a single year, which may indicate deteriorating supplier leverage or forced vendor financing arrangements rather than negotiating strength. Meanwhile, DSO has worsened from 43-51 days to 68 days in 2027Q1, suggesting slower customer collections, and DIO remains elevated at 161 days — indicating significant inventory holding costs that are typical of cannabis-sector working capital demands. The improvement in CCC, on the surface, appears operationally positive, but an analyst should question whether suppliers will continue to tolerate extended payment terms, particularly as TLRY's cash reserves have declined to $215 million.